672 related articles for article (PubMed ID: 25772748)
1. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
[TBL] [Abstract][Full Text] [Related]
2. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.
Kazankov K; Barrera F; Møller HJ; Rosso C; Bugianesi E; David E; Younes R; Esmaili S; Eslam M; McLeod D; Bibby BM; Vilstrup H; George J; Grønbaek H
Liver Int; 2016 Oct; 36(10):1549-57. PubMed ID: 27102725
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.
Laursen TL; Wong GL; Kazankov K; Sandahl T; Møller HJ; Hamilton-Dutoit S; George J; Chan HL; Grønbaek H
J Gastroenterol Hepatol; 2018 Feb; 33(2):484-491. PubMed ID: 28618015
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
[TBL] [Abstract][Full Text] [Related]
5. Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease.
Rødgaard-Hansen S; St George A; Kazankov K; Bauman A; George J; Grønbæk H; Jon Møller H
Scand J Clin Lab Invest; 2017 Nov; 77(7):498-504. PubMed ID: 28715286
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus.
Dultz G; Gerber L; Farnik H; Berger A; Vermehren J; Pleli T; Zeuzem S; Piiper A; Kronenberger B; Waidmann O
J Viral Hepat; 2015 Apr; 22(4):427-32. PubMed ID: 25181653
[TBL] [Abstract][Full Text] [Related]
7. The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children.
Kazankov K; Møller HJ; Lange A; Birkebaek NH; Holland-Fischer P; Solvig J; Hørlyck A; Kristensen K; Rittig S; Handberg A; Vilstrup H; Grønbaek H
Pediatr Obes; 2015 Jun; 10(3):226-33. PubMed ID: 25073966
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C.
Kazankov K; Barrera F; Møller HJ; Bibby BM; Vilstrup H; George J; Grønbaek H
Hepatology; 2014 Aug; 60(2):521-30. PubMed ID: 24623375
[TBL] [Abstract][Full Text] [Related]
9. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD.
Axelsson J; Møller HJ; Witasp A; Qureshi AR; Carrero JJ; Heimbürger O; Bárány P; Alvestrand A; Lindholm B; Moestrup SK; Stenvinkel P
Am J Kidney Dis; 2006 Dec; 48(6):916-25. PubMed ID: 17162146
[TBL] [Abstract][Full Text] [Related]
10. Performance of serum CD163 as a marker of fibrosis in patients with NAFLD.
Ragab HM; El Maksoud NA; Amin MA; Elaziz WA
Diabetes Metab Syndr; 2021; 15(1):87-92. PubMed ID: 33310266
[TBL] [Abstract][Full Text] [Related]
11. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.
Waidmann O; Köberle V; Bettinger D; Trojan J; Zeuzem S; Schultheiß M; Kronenberger B; Piiper A
J Hepatol; 2013 Oct; 59(4):769-79. PubMed ID: 23792028
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of circulating markers of hepatic apoptosis and inflammation in obese children with and without obstructive sleep apnea.
Alkhouri N; Kheirandish-Gozal L; Matloob A; Alonso-Álvarez ML; Khalyfa A; Terán-Santos J; Okwu V; Lopez R; Gileles-Hillel A; Dweik R; Gozal D
Sleep Med; 2015 Sep; 16(9):1031-5. PubMed ID: 26298775
[TBL] [Abstract][Full Text] [Related]
14. Expression of soluble sCD163 in serum of psoriatic patients is modulated by Goeckerman therapy.
Kondelkova K; Krejsek J; Borska L; Fiala Z; Hamakova K; Andrys C
Allergol Immunopathol (Madr); 2013; 41(3):158-62. PubMed ID: 22765877
[TBL] [Abstract][Full Text] [Related]
15. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
[TBL] [Abstract][Full Text] [Related]
16. The macrophage-specific serum marker, soluble CD163, is increased in obesity and reduced after dietary-induced weight loss.
Fjeldborg K; Christiansen T; Bennetzen M; J Møller H; Pedersen SB; Richelsen B
Obesity (Silver Spring); 2013 Dec; 21(12):2437-43. PubMed ID: 23512476
[TBL] [Abstract][Full Text] [Related]
17. Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma.
Kazankov K; Rode A; Simonsen K; Villadsen GE; Nicoll A; Møller HJ; Lim L; Angus P; Kronborg I; Arachchi N; Gorelik A; Liew D; Vilstrup H; Frystyk J; Grønbæk H
Scand J Clin Lab Invest; 2016; 76(1):64-73. PubMed ID: 26549495
[TBL] [Abstract][Full Text] [Related]
18. An alternatively activated macrophage marker CD163 in severely obese patients: the influence of very low-calorie diet and bariatric surgery.
Cinkajzlová A; Lacinová Z; Kloučková J; Kaválková P; Trachta P; Kosák M; Krátký J; Kasalický M; DoleŽalová K; Mráz M; Haluzík M
Physiol Res; 2017 Sep; 66(4):641-652. PubMed ID: 28406702
[TBL] [Abstract][Full Text] [Related]
19. Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs.
Greisen SR; Møller HJ; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Junker P; Østergaard M; Hvid M; Deleuran B
Clin Exp Rheumatol; 2015; 33(4):498-502. PubMed ID: 25962601
[TBL] [Abstract][Full Text] [Related]
20. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis.
Grønbaek H; Sandahl TD; Mortensen C; Vilstrup H; Møller HJ; Møller S
Aliment Pharmacol Ther; 2012 Jul; 36(2):173-80. PubMed ID: 22591184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
